Summary
30.40 0.23(0.76%)07/01/2024
Harmony Biosciences Holdings Inc (HRMY)
Harmony Biosciences Holdings Inc (HRMY)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 0.71 | 1.00 | 1.50 | -7.85 | -1.27 | -12.74 | 0.00 | -17.86 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 30.40 | |
| Open | 30.42 | |
| High | 31.55 | |
| Low | 29.94 | |
| Volume | 234,505 | |
| Change | 0.22 | |
| Change % | 0.71 | |
| Avg Volume (20 Days) | 288,077 | |
| Volume/Avg Volume (20 Days) Ratio | 0.81 | |
| 52 Week Range | 18.61 - 39.27 | |
| Price vs 52 Week High | -22.59% | |
| Price vs 52 Week Low | 63.35% | |
| Range | -0.07 | |
| Gap Up/Down | -1.47 | |
Fundamentals | ||
| Market Capitalization (Mln) | 1,713 | |
| EBIDTA | 85,118,000 | |
| PE Ratio | 195.9184 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 57.00 | |
| Book Value | 2.6020 | |
| Earnings Per Share | 0.1960 | |
| EPS Estimate Current Quarter | 0.2900 | |
| EPS Estimate Next Quarter | 0.4300 | |
| EPS Estimate Current Year | 0.6600 | |
| EPS Estimate Next Year | 2.2700 | |
| Diluted EPS (TTM) | 0.1960 | |
| Revenues | ||
| Profit Marging | 0.0432 | |
| Operating Marging (TTM) | 0.2464 | |
| Return on asset (TTM) | 0.1172 | |
| Return on equity (TTM) | 0.0947 | |
| Revenue TTM | 270,515,008 | |
| Revenue per share TTM | 4.7320 | |
| Quarterly Revenue Growth (YOY) | 0.7700 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 132,004,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 195.9184 | |
| Forward PE | 22.4215 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 14.6700 | |
| Revenue Enterprise Value | 8.2527 | |
| EBITDA Enterprise Value | 37.5786 | |
| Shares | ||
| Shares Outstanding | 58,471,500 | |
| Shares Float | 23,274,588 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 20.06 | |
| Institutions (%) | 79.82 | |
07/01 14:18 EST - investorplace.com
7 Undervalued Biotech Stocks to Buy for Big-Time Returns
Every investment category must answer the big question, why? For undervalued biotech stocks, it comes down to advantaging a supremely relevant sector without paying full price.
7 Undervalued Biotech Stocks to Buy for Big-Time Returns
Every investment category must answer the big question, why? For undervalued biotech stocks, it comes down to advantaging a supremely relevant sector without paying full price.
06/25 08:05 EST - prnewswire.com
HARMONY BIOSCIENCES ACKNOWLEDGES U.S. FOOD & DRUG ADMINISTRATION (FDA) ACTION DENYING THE CITIZEN PETITION FOR WAKIX® (PITOLSIANT)
FDA confirms the favorable benefit-risk profile of WAKIX Harmony Biosciences focused on continuing to advance its pipeline assets across three rare CNS franchises; anticipates at least one new product or indication launch annually over the next five years PLYMOUTH MEETING, Pa. , June 25, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that the U.S. Food and Drug Administration denied the Citizen Petition filed by a short seller claiming that WAKIX is not safe and effective for the treatment of excessive daytime sleepiness (EDS) and cataplexy in adults with narcolepsy.
HARMONY BIOSCIENCES ACKNOWLEDGES U.S. FOOD & DRUG ADMINISTRATION (FDA) ACTION DENYING THE CITIZEN PETITION FOR WAKIX® (PITOLSIANT)
FDA confirms the favorable benefit-risk profile of WAKIX Harmony Biosciences focused on continuing to advance its pipeline assets across three rare CNS franchises; anticipates at least one new product or indication launch annually over the next five years PLYMOUTH MEETING, Pa. , June 25, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that the U.S. Food and Drug Administration denied the Citizen Petition filed by a short seller claiming that WAKIX is not safe and effective for the treatment of excessive daytime sleepiness (EDS) and cataplexy in adults with narcolepsy.
06/24 12:56 EST - investorplace.com
7 Biotech Stocks to Buy on the Dip: June 2024
Fundamentally, the biotechnology sphere enjoys a powerful catalyst: wealth without health means nothing. Yes, it's important to save money and invest for the future.
7 Biotech Stocks to Buy on the Dip: June 2024
Fundamentally, the biotechnology sphere enjoys a powerful catalyst: wealth without health means nothing. Yes, it's important to save money and invest for the future.
06/24 07:00 EST - prnewswire.com
HARMONY BIOSCIENCES RECEIVES U.S. FOOD AND DRUG ADMINISTRATION APPROVAL FOR WAKIX® (PITOLISANT) IN PEDIATRIC PATIENTS WITH NARCOLEPSY
PLYMOUTH MEETING, Pa. , June 24, 2024 /PRNewswire/ -- Harmony Biosciences (Nasdaq: HRMY) today announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug Application (sNDA) for WAKIX® (pitolisant) tablets for the treatment of excessive daytime sleepiness (EDS) in pediatric patients 6 years of age and older with narcolepsy.
HARMONY BIOSCIENCES RECEIVES U.S. FOOD AND DRUG ADMINISTRATION APPROVAL FOR WAKIX® (PITOLISANT) IN PEDIATRIC PATIENTS WITH NARCOLEPSY
PLYMOUTH MEETING, Pa. , June 24, 2024 /PRNewswire/ -- Harmony Biosciences (Nasdaq: HRMY) today announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug Application (sNDA) for WAKIX® (pitolisant) tablets for the treatment of excessive daytime sleepiness (EDS) in pediatric patients 6 years of age and older with narcolepsy.
06/05 08:05 EST - prnewswire.com
HARMONY BIOSCIENCES PRESENTS POSITIVE DATA FOR PITOLISANT IN THE TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS AND FATIGUE IN MYOTONIC DYSTROPHY TYPE 1
PLYMOUTH MEETING, Pa. , June 5, 2024 /PRNewswire/ -- Harmony Biosciences (Nasdaq: HRMY) presented data from its Phase 2 signal detection study showing that pitolisant reduced excessive daytime sleepiness (EDS) and fatigue in adults with Myotonic dystrophy Type 1 (DM1).
HARMONY BIOSCIENCES PRESENTS POSITIVE DATA FOR PITOLISANT IN THE TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS AND FATIGUE IN MYOTONIC DYSTROPHY TYPE 1
PLYMOUTH MEETING, Pa. , June 5, 2024 /PRNewswire/ -- Harmony Biosciences (Nasdaq: HRMY) presented data from its Phase 2 signal detection study showing that pitolisant reduced excessive daytime sleepiness (EDS) and fatigue in adults with Myotonic dystrophy Type 1 (DM1).
05/28 08:05 EST - prnewswire.com
HARMONY BIOSCIENCES TO PARTICIPATE IN GOLDMAN SACHS 45th ANNUAL GLOBAL HEALTHCARE CONFERENCE
PLYMOUTH MEETING, Pa. , May 28, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in a fireside chat at the upcoming Goldman Sachs 45th Annual Global Healthcare Conference in Miami Beach, FL on Monday, June 10, 2024, at 9:20 a.m.
HARMONY BIOSCIENCES TO PARTICIPATE IN GOLDMAN SACHS 45th ANNUAL GLOBAL HEALTHCARE CONFERENCE
PLYMOUTH MEETING, Pa. , May 28, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in a fireside chat at the upcoming Goldman Sachs 45th Annual Global Healthcare Conference in Miami Beach, FL on Monday, June 10, 2024, at 9:20 a.m.
05/20 05:01 EST - https://www.defenseworld.net
Amalgamated Bank Lowers Position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)
Amalgamated Bank lessened its position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY – Free Report) by 8.1% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 14,003 shares of the company’s stock after selling 1,239 shares during the quarter. Amalgamated Bank’s holdings in Harmony Biosciences were worth $452,000 as of its most recent filing with the Securities & Exchange Commission. A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Summit Global Investments purchased a new position in shares of Harmony Biosciences in the 4th quarter valued at approximately $522,000. Los Angeles Capital Management LLC increased its position in Harmony Biosciences by 218.0% during the 4th quarter. Los Angeles Capital Management LLC now owns 24,148 shares of the company’s stock valued at $780,000 after buying an additional 16,555 shares in the last quarter. Jackson Creek Investment Advisors LLC bought a new position in Harmony Biosciences during the 4th quarter valued at approximately $991,000. Paradiem LLC increased its position in Harmony Biosciences by 38.7% during the 4th quarter. Paradiem LLC now owns 107,031 shares of the company’s stock valued at $3,457,000 after buying an additional 29,847 shares in the last quarter. Finally, Truist Financial Corp bought a new position in Harmony Biosciences during the 4th quarter valued at approximately $297,000. Hedge funds and other institutional investors own 86.23% of the company’s stock. Wall Street Analysts Forecast Growth A number of research analysts recently weighed in on HRMY shares. Mizuho reduced their price objective on Harmony Biosciences from $42.00 to $40.00 and set a “buy” rating for the company in a research report on Tuesday, February 27th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $49.00 price objective on shares of Harmony Biosciences in a research report on Friday, April 12th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $50.00 target price on shares of Harmony Biosciences in a report on Tuesday, April 30th. Two research analysts have rated the stock with a sell rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, Harmony Biosciences currently has an average rating of “Moderate Buy” and an average target price of $40.63. Read Our Latest Report on HRMY Harmony Biosciences Stock Down 1.0 % Harmony Biosciences stock opened at $29.03 on Monday. The company has a current ratio of 3.11, a quick ratio of 3.07 and a debt-to-equity ratio of 0.34. Harmony Biosciences Holdings, Inc. has a 12 month low of $18.61 and a 12 month high of $39.26. The firm has a market cap of $1.65 billion, a price-to-earnings ratio of 12.57, a PEG ratio of 0.47 and a beta of 0.75. The stock has a fifty day simple moving average of $30.88 and a two-hundred day simple moving average of $30.86. Harmony Biosciences (NASDAQ:HRMY – Get Free Report) last issued its quarterly earnings data on Tuesday, April 30th. The company reported $0.67 EPS for the quarter, topping the consensus estimate of $0.60 by $0.07. Harmony Biosciences had a return on equity of 28.26% and a net margin of 22.30%. The company had revenue of $154.62 million during the quarter, compared to analyst estimates of $154.10 million. During the same quarter in the previous year, the company posted $0.48 earnings per share. Harmony Biosciences’s revenue was up 29.8% compared to the same quarter last year. Equities analysts predict that Harmony Biosciences Holdings, Inc. will post 2.53 EPS for the current fiscal year. Insider Buying and Selling In related news, insider Jeffrey Dierks sold 11,979 shares of Harmony Biosciences stock in a transaction on Friday, March 15th. The stock was sold at an average price of $32.00, for a total value of $383,328.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 30.80% of the stock is currently owned by corporate insiders. About Harmony Biosciences (Free Report) Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. Read More Five stocks we like better than Harmony Biosciences The How And Why of Investing in Oil Stocks MarketBeat Week in Review – 5/13 – 5/17 Canadian Penny Stocks: Can They Make You Rich? Take-Two Interactive Software Offers 2nd Chance for Investors Transportation Stocks Investing Deere & Company’s Q2 Report: Strong Revenue, Cautious Outlook Want to see what other hedge funds are holding HRMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY – Free Report).
Amalgamated Bank Lowers Position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)
Amalgamated Bank lessened its position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY – Free Report) by 8.1% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 14,003 shares of the company’s stock after selling 1,239 shares during the quarter. Amalgamated Bank’s holdings in Harmony Biosciences were worth $452,000 as of its most recent filing with the Securities & Exchange Commission. A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Summit Global Investments purchased a new position in shares of Harmony Biosciences in the 4th quarter valued at approximately $522,000. Los Angeles Capital Management LLC increased its position in Harmony Biosciences by 218.0% during the 4th quarter. Los Angeles Capital Management LLC now owns 24,148 shares of the company’s stock valued at $780,000 after buying an additional 16,555 shares in the last quarter. Jackson Creek Investment Advisors LLC bought a new position in Harmony Biosciences during the 4th quarter valued at approximately $991,000. Paradiem LLC increased its position in Harmony Biosciences by 38.7% during the 4th quarter. Paradiem LLC now owns 107,031 shares of the company’s stock valued at $3,457,000 after buying an additional 29,847 shares in the last quarter. Finally, Truist Financial Corp bought a new position in Harmony Biosciences during the 4th quarter valued at approximately $297,000. Hedge funds and other institutional investors own 86.23% of the company’s stock. Wall Street Analysts Forecast Growth A number of research analysts recently weighed in on HRMY shares. Mizuho reduced their price objective on Harmony Biosciences from $42.00 to $40.00 and set a “buy” rating for the company in a research report on Tuesday, February 27th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $49.00 price objective on shares of Harmony Biosciences in a research report on Friday, April 12th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $50.00 target price on shares of Harmony Biosciences in a report on Tuesday, April 30th. Two research analysts have rated the stock with a sell rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, Harmony Biosciences currently has an average rating of “Moderate Buy” and an average target price of $40.63. Read Our Latest Report on HRMY Harmony Biosciences Stock Down 1.0 % Harmony Biosciences stock opened at $29.03 on Monday. The company has a current ratio of 3.11, a quick ratio of 3.07 and a debt-to-equity ratio of 0.34. Harmony Biosciences Holdings, Inc. has a 12 month low of $18.61 and a 12 month high of $39.26. The firm has a market cap of $1.65 billion, a price-to-earnings ratio of 12.57, a PEG ratio of 0.47 and a beta of 0.75. The stock has a fifty day simple moving average of $30.88 and a two-hundred day simple moving average of $30.86. Harmony Biosciences (NASDAQ:HRMY – Get Free Report) last issued its quarterly earnings data on Tuesday, April 30th. The company reported $0.67 EPS for the quarter, topping the consensus estimate of $0.60 by $0.07. Harmony Biosciences had a return on equity of 28.26% and a net margin of 22.30%. The company had revenue of $154.62 million during the quarter, compared to analyst estimates of $154.10 million. During the same quarter in the previous year, the company posted $0.48 earnings per share. Harmony Biosciences’s revenue was up 29.8% compared to the same quarter last year. Equities analysts predict that Harmony Biosciences Holdings, Inc. will post 2.53 EPS for the current fiscal year. Insider Buying and Selling In related news, insider Jeffrey Dierks sold 11,979 shares of Harmony Biosciences stock in a transaction on Friday, March 15th. The stock was sold at an average price of $32.00, for a total value of $383,328.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 30.80% of the stock is currently owned by corporate insiders. About Harmony Biosciences (Free Report) Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. Read More Five stocks we like better than Harmony Biosciences The How And Why of Investing in Oil Stocks MarketBeat Week in Review – 5/13 – 5/17 Canadian Penny Stocks: Can They Make You Rich? Take-Two Interactive Software Offers 2nd Chance for Investors Transportation Stocks Investing Deere & Company’s Q2 Report: Strong Revenue, Cautious Outlook Want to see what other hedge funds are holding HRMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY – Free Report).
05/01 13:46 EST - zacks.com
Looking for a Growth Stock? 3 Reasons Why Harmony Biosciences (HRMY) is a Solid Choice
Harmony Biosciences (HRMY) could produce exceptional returns because of its solid growth attributes.
Looking for a Growth Stock? 3 Reasons Why Harmony Biosciences (HRMY) is a Solid Choice
Harmony Biosciences (HRMY) could produce exceptional returns because of its solid growth attributes.
05/01 12:41 EST - zacks.com
HRMY or TECH: Which Is the Better Value Stock Right Now?
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Harmony Biosciences Holdings, Inc. (HRMY) and Techne (TECH). But which of these two stocks offers value investors a better bang for their buck right now?
HRMY or TECH: Which Is the Better Value Stock Right Now?
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Harmony Biosciences Holdings, Inc. (HRMY) and Techne (TECH). But which of these two stocks offers value investors a better bang for their buck right now?
04/30 13:49 EST - seekingalpha.com
Harmony Biosciences Holdings, Inc (HRMY) Q1 2024 Earnings Call Transcript
Harmony Biosciences Holdings, Inc (NASDAQ:HRMY ) Q1 2024 Earnings Conference Call April 30, 2024 8:30 AM ET Company Participants Luis Sanay - Head of Investor Relations Jeffrey Dayno - President & Chief Executive Officer Jeffrey Dierks - Chief Commercial Officer Kumar Budur - Chief Medical Officer Sandip Kapadia - Chief Financial Officer & Chief Administrative Officer Conference Call Participants Charles Duncan - Cantor Fitzgerald Francois Brisebois - Oppenheimer Ami Fadia - Needham David Amsellem - Piper Sandler Graig Suvannavejh - Mizuho Corinne Jenkins - Goldman Sachs Jason Gerberry - Bank of America Danielle Brill - Raymond James Operator Good morning. My name is Madison, and I will be your conference operator today.
Harmony Biosciences Holdings, Inc (HRMY) Q1 2024 Earnings Call Transcript
Harmony Biosciences Holdings, Inc (NASDAQ:HRMY ) Q1 2024 Earnings Conference Call April 30, 2024 8:30 AM ET Company Participants Luis Sanay - Head of Investor Relations Jeffrey Dayno - President & Chief Executive Officer Jeffrey Dierks - Chief Commercial Officer Kumar Budur - Chief Medical Officer Sandip Kapadia - Chief Financial Officer & Chief Administrative Officer Conference Call Participants Charles Duncan - Cantor Fitzgerald Francois Brisebois - Oppenheimer Ami Fadia - Needham David Amsellem - Piper Sandler Graig Suvannavejh - Mizuho Corinne Jenkins - Goldman Sachs Jason Gerberry - Bank of America Danielle Brill - Raymond James Operator Good morning. My name is Madison, and I will be your conference operator today.
04/30 07:05 EST - globenewswire.com
Harmony Biosciences Reports Strong First Quarter Financial Results and Acceleration of Its Growth Strategy; Advances Pitolisant Franchise to Extend Revenue Potential Beyond 2040; Strenghtens Sleep/Wake Leadership and Diversifies Into Rare Epilepsy
WAKIX® (pitolisant) Net Revenue of $154.6 Million for First Quarter 2024; ~30% Growth Year-over-Year Supplemental New Drug Application for Pitolisant in Idiopathic Hypersomnia Planned for Second Half 2024 On Track Toward Pediatric Exclusivity to Extend WAKIX Exclusivity to September 2030: Pediatric Narcolepsy sNDA PDUFA Date of June 21, 2024; PWS Phase 3 TEMPO Study Initiated in March 2024 Pitolisant Franchise Revenue Potential Extended Beyond 2040 With Next-Generation Formulations; Reports Positive Pharmacokinetic Data on Next-Generation Formulation 1 (NG1); PDUFA Expected in 2026 Strengthens Leadership Position in Sleep/Wake with Licensing of TPM-1116, a Highly Potent and Selective Oral Orexin-2 Receptor Agonist Establishes Potential Billion Dollar Plus Rare Epilepsy Franchise Through Acquisition of Epygenix Therapeutics, Inc. Reiterates 2024 Net Product Revenue Guidance of $700 - $720 Million Conference Call and Webcast to be Held Today at 8:30 a.m. ET PLYMOUTH MEETING, Pa.
Harmony Biosciences Reports Strong First Quarter Financial Results and Acceleration of Its Growth Strategy; Advances Pitolisant Franchise to Extend Revenue Potential Beyond 2040; Strenghtens Sleep/Wake Leadership and Diversifies Into Rare Epilepsy
WAKIX® (pitolisant) Net Revenue of $154.6 Million for First Quarter 2024; ~30% Growth Year-over-Year Supplemental New Drug Application for Pitolisant in Idiopathic Hypersomnia Planned for Second Half 2024 On Track Toward Pediatric Exclusivity to Extend WAKIX Exclusivity to September 2030: Pediatric Narcolepsy sNDA PDUFA Date of June 21, 2024; PWS Phase 3 TEMPO Study Initiated in March 2024 Pitolisant Franchise Revenue Potential Extended Beyond 2040 With Next-Generation Formulations; Reports Positive Pharmacokinetic Data on Next-Generation Formulation 1 (NG1); PDUFA Expected in 2026 Strengthens Leadership Position in Sleep/Wake with Licensing of TPM-1116, a Highly Potent and Selective Oral Orexin-2 Receptor Agonist Establishes Potential Billion Dollar Plus Rare Epilepsy Franchise Through Acquisition of Epygenix Therapeutics, Inc. Reiterates 2024 Net Product Revenue Guidance of $700 - $720 Million Conference Call and Webcast to be Held Today at 8:30 a.m. ET PLYMOUTH MEETING, Pa.
04/30 07:00 EST - prnewswire.com
Harmony Biosciences Acquires Epygenix Therapeutics, Inc., Adding Late-Stage Epilepsy Franchise to Growing Pipeline of Innovative CNS Assets
Lead Candidate, EPX-100, Holds Orphan Drug and Rare Pediatric Disease Designations EPX-100 in Pivotal Registrational Trial for Dravet Syndrome; Topline Data Expected in 2026 Plan to Initiate Phase 3 Trial for Lennox-Gastaut Syndrome in Second Half of 2024 Potential Billion Dollar Plus Market Opportunity in Rare Epilepsy PLYMOUTH MEETING, Pa. , April 30, 2024 /PRNewswire/ -- Harmony Biosciences (Nasdaq: HRMY), today announced the acquisition of Epygenix Therapeutics, Inc., accelerating its growth strategy by adding a rare epilepsy franchise to its expanding late-stage pipeline of innovative CNS assets.
Harmony Biosciences Acquires Epygenix Therapeutics, Inc., Adding Late-Stage Epilepsy Franchise to Growing Pipeline of Innovative CNS Assets
Lead Candidate, EPX-100, Holds Orphan Drug and Rare Pediatric Disease Designations EPX-100 in Pivotal Registrational Trial for Dravet Syndrome; Topline Data Expected in 2026 Plan to Initiate Phase 3 Trial for Lennox-Gastaut Syndrome in Second Half of 2024 Potential Billion Dollar Plus Market Opportunity in Rare Epilepsy PLYMOUTH MEETING, Pa. , April 30, 2024 /PRNewswire/ -- Harmony Biosciences (Nasdaq: HRMY), today announced the acquisition of Epygenix Therapeutics, Inc., accelerating its growth strategy by adding a rare epilepsy franchise to its expanding late-stage pipeline of innovative CNS assets.
04/16 08:05 EST - prnewswire.com
HARMONY BIOSCIENCES TO REPORT FIRST QUARTER 2024 FINANCIAL RESULTS ON APRIL 30, 2024
PLYMOUTH MEETING, Pa. , April 16, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report first quarter 2024 financial results on Tuesday, April 30, 2024, before the open of the U.S. financial markets.
HARMONY BIOSCIENCES TO REPORT FIRST QUARTER 2024 FINANCIAL RESULTS ON APRIL 30, 2024
PLYMOUTH MEETING, Pa. , April 16, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report first quarter 2024 financial results on Tuesday, April 30, 2024, before the open of the U.S. financial markets.
04/11 08:05 EST - prnewswire.com
HARMONY BIOSCIENCES ANNOUNCES EXCLUSIVE AGREEMENT TO DEVELOP AND COMMERCIALIZE TPM-1116, A HIGHLY POTENT AND SELECTIVE ORAL OREXIN-2 RECEPTOR AGONIST
PLYMOUTH MEETING, Pa. , April 11, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced an exclusive licensing agreement with Bioprojet to develop, manufacture and commercialize TPM-1116, a highly potent and selective oral orexin-2 receptor (OX2R) agonist that will be evaluated for the treatment of narcolepsy and other sleep/wake disorders.
HARMONY BIOSCIENCES ANNOUNCES EXCLUSIVE AGREEMENT TO DEVELOP AND COMMERCIALIZE TPM-1116, A HIGHLY POTENT AND SELECTIVE ORAL OREXIN-2 RECEPTOR AGONIST
PLYMOUTH MEETING, Pa. , April 11, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced an exclusive licensing agreement with Bioprojet to develop, manufacture and commercialize TPM-1116, a highly potent and selective oral orexin-2 receptor (OX2R) agonist that will be evaluated for the treatment of narcolepsy and other sleep/wake disorders.
04/03 08:05 EST - prnewswire.com
HARMONY BIOSCIENCES INITIATES GLOBAL PHASE 3 REGISTRATIONAL TRIAL (TEMPO STUDY) OF PITOLISANT IN PATIENTS WITH PRADER-WILLI SYNDROME
PLYMOUTH MEETING, Pa. , April 3, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY) has initiated its global Phase 3 registrational trial, the TEMPO study, to evaluate the safety and efficacy of pitolisant as a treatment for excessive daytime sleepiness (EDS) and behavioral symptoms in patients aged six years and older with Prader-Willi syndrome (PWS).
HARMONY BIOSCIENCES INITIATES GLOBAL PHASE 3 REGISTRATIONAL TRIAL (TEMPO STUDY) OF PITOLISANT IN PATIENTS WITH PRADER-WILLI SYNDROME
PLYMOUTH MEETING, Pa. , April 3, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY) has initiated its global Phase 3 registrational trial, the TEMPO study, to evaluate the safety and efficacy of pitolisant as a treatment for excessive daytime sleepiness (EDS) and behavioral symptoms in patients aged six years and older with Prader-Willi syndrome (PWS).
03/26 08:05 EST - prnewswire.com
HARMONY BIOSCIENCES TO PARTICIPATE IN 23RD ANNUAL NEEDHAM VIRTUAL HEALTHCARE CONFERENCE
PLYMOUTH MEETING, Pa. , March 26, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in a fireside chat at the upcoming 23rd Annual Needham Virtual Healthcare Conference on Monday, April 8, 2024, at 9:30 a.m.
HARMONY BIOSCIENCES TO PARTICIPATE IN 23RD ANNUAL NEEDHAM VIRTUAL HEALTHCARE CONFERENCE
PLYMOUTH MEETING, Pa. , March 26, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in a fireside chat at the upcoming 23rd Annual Needham Virtual Healthcare Conference on Monday, April 8, 2024, at 9:30 a.m.
02/28 08:05 EST - prnewswire.com
HARMONY BIOSCIENCES TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES
PLYMOUTH MEETING, Pa. , Feb. 28, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in the following upcoming investor conferences: Leerink Partners Global Biopharma Conference 2024 Location: Miami Fireside Chat: Monday, March 11, 2024, at 12:40 p.m.
HARMONY BIOSCIENCES TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES
PLYMOUTH MEETING, Pa. , Feb. 28, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in the following upcoming investor conferences: Leerink Partners Global Biopharma Conference 2024 Location: Miami Fireside Chat: Monday, March 11, 2024, at 12:40 p.m.
02/23 12:41 EST - zacks.com
HRMY vs. TECH: Which Stock Is the Better Value Option?
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Harmony Biosciences Holdings, Inc. (HRMY) and Techne (TECH). But which of these two stocks is more attractive to value investors?
HRMY vs. TECH: Which Stock Is the Better Value Option?
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Harmony Biosciences Holdings, Inc. (HRMY) and Techne (TECH). But which of these two stocks is more attractive to value investors?
02/22 09:45 EST - zacks.com
Harmony Biosciences Holdings, Inc. (HRMY) Misses Q4 Earnings and Revenue Estimates
Harmony Biosciences Holdings, Inc. (HRMY) came out with quarterly earnings of $0.45 per share, missing the Zacks Consensus Estimate of $0.74 per share. This compares to earnings of $1.01 per share a year ago.
Harmony Biosciences Holdings, Inc. (HRMY) Misses Q4 Earnings and Revenue Estimates
Harmony Biosciences Holdings, Inc. (HRMY) came out with quarterly earnings of $0.45 per share, missing the Zacks Consensus Estimate of $0.74 per share. This compares to earnings of $1.01 per share a year ago.
02/22 07:30 EST - globenewswire.com
Harmony Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
WAKIX® (pitolisant) Net Revenue of $168.4 Million for Fourth Quarter and $582.0 Million for Full Year 2023; Representing Growth of ~31% and ~33%, Respectively
Harmony Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
WAKIX® (pitolisant) Net Revenue of $168.4 Million for Fourth Quarter and $582.0 Million for Full Year 2023; Representing Growth of ~31% and ~33%, Respectively